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Abstract
Purpose of review—The long-lived viral reservoir is a major obstacle to achieving a cure for 
HIV. Therapeutic strategies, such as early antiretroviral therapy (ART), may be a prerequisite to 
achieving long-term control of viral replication upon ART withdrawal.
Recent findings—HIV persistence is established early in acute HIV infection (AHI) with 
infection in long-lived memory CD4+ T cells. Studies conducted in nonhuman primates have 
suggested that this could occur as early as 3 days postinfection; however, the timing in humans is 
uncertain. ART during AHI significantly restricts the HIV reservoirs as compared with later 
treatment. Early ART, particularly prior to the detection of HIV immunoglobulin M, may also 
reduce the contribution of the long-lived central memory CD4+ T cells to the total HIV reservoir, a 
profile observed in individuals who naturally control HIV without ART.
Summary—It is clear that early ART has a greater impact in limiting the HIV reservoirs than 
later treatment. However, latently infected long-lived memory CD4+ T cells persist in most early 
treated individuals. Therefore, additional interventions will likely be required to eliminate all cells 
capable of producing replication-competent virus but treatment in AHI may be the critical first 
step in containing the HIV reservoirs.
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The discovery of a small pool of latently infected cells that persist in HIV-infected 
individuals receiving suppressive antiretroviral therapy (ART) has considerably dampened 
the hope of eradicating HIV with ART alone [1–3]. This long-lived reservoir is often 
considered the major obstacle to achieving a cure for HIV and therapeutic strategies that 
could limit its size may be a prerequisite to achieving control of viral replication upon ART 
withdrawal, which is also called HIV remission [4,5]. Current evidence suggests that ART 
instituted early during acute HIV infection (AHI) is key to containing HIV reservoir 
establishment, particularly in long-lived CD4+ T cells, providing a basis for its critical role 
in achieving HIV remission [6■,7,8]. Indeed, a prime example is the case of the Mississippi 
child who started ART by 2 days of life for 18 months and subsequently was able to remain 
with low HIV reservoirs and virally suppressed for 27 months in the absence of ART [9,10]. 
Similarly, the VISCONTI cohort of adults in France was treated within the first 2 months of 
infection and was able to control viremia without ART for more than 5 years [11■■]. 
Through key published works, this review covers the timing and mechanisms of HIV 
reservoir establishment and the effects of early ART on the HIV reservoirs as well as future 
research directions.
The latent HIV reservoir is established early after infection
The mechanisms responsible for the establishment of HIV latency are not fully elucidated. 
Latently infected cells are rare in vivo and appear to arise when activated CD4+ T cells, the 
major targets cells for HIV infection, become infected and survive long enough to revert 
back to a resting memory state, which is nonpermissive for viral gene expression [12]. An 
alternative model proposes that HIV latency is directly established in resting CD4+ T cells, 
following interaction with dendritic cells and/or specific chemokines [13,14].
No matter how latently infected cells are generated, several lines of evidence clearly indicate 
that the latent reservoir is established early in infection, indicating that one or both of these 
mechanisms occur within the first few days or weeks after transmission. Indeed, initiation of 
ART as early as 10 days after the onset of symptoms of primary HIV infection (PHI) does 
not prevent the generation of latently infected carrying infectious HIV despite the successful 
control of plasma viremia shortly after institution of therapy [15■]. Studies in nonhuman 
primates (NHPs), which have the advantage of precisely defining the time and location of 
the reservoir establishment, have also demonstrated that lentiviruses seed their reservoir 
within a few days post-infection; large numbers of resting CD4+ T cells carry integrated 
simian immunodeficiency virus (SIV), and simian human immunodeficiency virus DNA 
[16] can be detected at the earliest stage of infection. In line with these results, Whitney et 
al. [17■■] recently demonstrated that treatment with ART 3 days post-SIVmac251 infection 
in rhesus macaques blocks the emergence of viral RNA and proviral DNA in peripheral 
blood but does not prevent the establishment of a viral reservoir in tissues. After 
discontinuation of ART following 24 weeks of fully suppressive therapy, virus rebounded in 
all animals [17■■]. These data indicate that the viral reservoir could be seeded substantially 
earlier than previously assumed [5]. Another study in SIVmac239-infected rhesus macaques 
showed that ART initiated prior to peak virus replication (day 12) significantly limits 
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systemic virus dissemination and seeding of the reservoir in the peripheral blood and 
lymphoid tissues [18]. Notwithstanding the important information generated by these studies 
conducted in NHP, it is crucial to caution their application to HIV infection in humans as 
SIV and HIV may establish their reservoir in distinct cells and tissues, and with different 
efficiency and kinetics. For instance, resting CD4+ T and myeloid cells are essentially 
resistant to HIV infection due to the restriction factor, Sterile alpha motif domain-containing 
protein 1 and HD domain-containing protein 1 (SAMHD1) [19,20–22], a mechanism that is 
counteracted by the SIV protein vpx, which is absent in HIV-1. This suggests that SIV may 
be more prone to directly establishing latency in resting CD4+ T cells and myeloid cells 
when compared with HIV. Moreover, the amount of virus used to efficiently infect NHPs is 
usually much higher than the ones that cause natural HIV transmission in humans and ART 
may not be as effective in NHPs as in HIV-infected patients. Therefore, the establishment of 
latent viral reservoir in humans and NHPs may differ in numerous ways, and further studies 
are warranted to demonstrate that these experimental models can be used to investigate the 
mechanisms responsible for the establishment and persistence of the long-lived HIV 
reservoir in infected individuals.
Early antiretroviral therapy limits the size of the latent HIV reservoir
Although the reservoir is seeded very early in infection, the beneficial effect of starting ART 
during the first weeks or months after infection to reduce the size of the latent reservoir has 
been reported in numerous studies. Strain et al. [23■■] reported that after 12 months of 
ART, replication-competent virus could not be detected in all patients who initiated 
treatment before seroconversion, nor in the majority of individuals who initiated ART in the 
first 6 months after seroconversion [23■■]. These observations were confirmed in several 
studies indicating that HIV-infected individuals who start ART within the first few months 
of HIV infection display a reservoir of smaller magnitude compared with those who start 
later in infection [6■,24■–26■,27■■]. Of note, the association between early ART initiation 
and a reduced size of the reservoir has been reported in multiple groups of patients using 
different assays including total HIV DNA [23■■,25■,26■,27■■], integrated DNA [24■,
27■■], as well as the quantitative viral outgrowth assay [6■,23■■,27■■]. Importantly, there 
is a gradual increase in the size of the reservoir during the first few weeks after infection. 
Individuals who start ART at the Fiebig [28] I stage of the disease [HIV RNA+ , p24 
antigen-, HIV Immunoglobulin M (IgM-)] show a significantly lower frequency of CD4+ T 
cells harboring integrated HIV DNA when compared to Fiebig II (HIV RNA+, p24 antigen
+ , HIV IgM–) and Fiebig III (HIV IgM+, HIV IgG–) individuals [25■]. Therefore, the 
benefits of early ART may be maximal during the first few weeks of infection.
The decay of the latent HIV reservoir may also be faster in individuals who start ART early 
after infection [27■■,29■], although the limited size of the initial pool of latently infected 
CD4+ T cells has been proposed to be the most important factor contributing to a smaller 
size of the reservoir after several years of therapy. Archin et al. [6■] demonstrated that 
although the frequency of cells harboring replication-competent HIV declines after the first 
year of ART in most acutely infected patients, no further decay is noted when this frequency 
reaches very low levels (less than 0.5 cells per million). Therefore, a subset of latently 
infected cells may persist indefinitely, even in patients who have started ART during acute 
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infection. The identification of the phenotype of these cells, in which HIV may persist for 
decades, is currently an area of intense investigation. Indeed, the composition of the 
reservoir (i.e., its distribution in distinct memory CD4+ T cell subsets) may provide crucial 
information on the mechanisms of HIV persistence, and several recent studies indicate that 
early ART greatly influences this parameter.
Early antiretroviral therapy alters the distribution of the reservoir in CD4+ T-cell subsets
Resting memory CD4+ T cells are the predominantly infected cells in virally suppressed 
patients. The use of a combination of markers expressed by memory CD4+ T cells has led to 
the identification of three cellular reservoirs in which HIV persists after prolonged 
suppressive ART, namely central (TCM), transitional (TTM) and effector (TEM) memory 
CD4+ T cells [24■,30] (Fig. 1). Because of their very distinct functional and phenotypic 
properties [31], these three cellular reservoirs may support viral persistence through 
different mechanisms. For instance, the drastic differences in the activation status of TCM 
and TEM cells [24■,32] suggest that the former might represent an ideal reservoir for latent 
HIV, whereas the latter may be more prone to support residual levels of viral replication in 
the face of ART. The relative contribution of each subset to the pool of HIV-infected cells is 
highly variable between HIV-infected individuals [24■]. Several recent studies suggest that 
a relatively low infection frequency of TCM cells may be strongly associated with lack of 
disease progression in a variety of apparently unrelated clinical scenarios in untreated 
individuals. Long-term nonprogressors (LTNPs) display a low infection frequency of TCM 
cells, which is associated with an increased size of the TCM pool and a greater number of 
anti-gag CD8+ T cells. Of note, TCM from HLAB27/B57 LTNPs are markedly less infected 
than TCM from individuals who do not bear these protective alleles [33]. In addition, in the 
recently described VISCONTI cohort of posttreatment controllers (PTCs), who initiated 
ART early in infection and naturally control HIV replication in the absence of ART, TCM 
contribute very minimally to the total HIV reservoir [11■■]. Taken together, the relative 
protection of TCM cells in LTNPs and PTCs suggests that a TCM compartment devoid of 
HIV may be an important correlate of natural control of HIV replication.
Can early ART initiation reproduces this skewed distribution of the reservoir by protecting 
TCM cells from infection? Preliminary data generated on samples from the RV254 study, an 
AHI study conducted by the Thai Red Cross AIDS Research Center and the US Military 
HIV Research Program, indicate that very early ART efficiently protects all memory CD4+ 
T-cell subsets from infection, including the long-lived TCM cells [7]. This is in agreement 
with other studies investigating the frequency of infection of distinct memory CD4+ T-cell 
subsets in study participants who initiated ART early in infection [8,26■,27■■]. Whether 
the TCM subset is more protected than the other subset by early ART is still unclear.
In addition to TCM, TTM and TEM cells, the recently described stem cell memory T cells, 
which share functional and self-renewal properties with TCM cells [34], may represent an 
additional relevant reservoir for HIV [35]. Importantly, early ART may significantly reduce 
the contribution of this extremely long-lived subset to the overall HIV reservoir [27■■].
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Clinical trials of early antiretroviral therapy and the HIV reservoirs
There are, so far, only a limited number of studies evaluating the impact of ART initiated in 
AHI on the HIV reservoirs. A major limitation is the difficulty in identifying people in AHI; 
this is a narrow window that spans the first 4 weeks of infection when the HIV IgG antibody 
response is not yet detected by standard assays [28,36]. The diagnosis generally requires 
nucleic acid testing that is costly and not part of standard testing algorithms in most settings. 
Thus, studies of acutely treated individuals are usually small. The immediate initiation of 
ART is also challenging, and in many studies, ART is initiated weeks or months after AHI is 
identified.
Table 1 summarizes the findings of selected studies published between 2005 and 2014 [6■,
25■, 27■■,37–39,40■■,41,42■]. Most enrolled less than 40 participants. They included 
individuals treated within a few weeks to 6 months after the onset of HIV with a handful 
including those treated during the earliest stages of AHI prior to HIV IgM detection [25■,
42■]. These studies consistently demonstrated the superiority of early ART over late 
treatment in reducing the HIV reservoir size as defined by HIV DNA levels (total and 
integrated, 2-long terminal repeat (LTR) circles 2-LTR circles) and frequencies of resting 
CD4+ T cells that are capable of producing replication-competent virus. Occurrence of low-
level viremia measured by single-copy HIV RNA assay is also less with early ART [6■]. 
The frequency of infected cells in the gastrointestinal tract was evaluated in two studies that 
observed a statistically significant decline in HIV DNA after early ART [25■,41]. Studies 
comparing standard vs. regimens intensified with integrase and entry inhibitors did not show 
a superior effect of the latter regimen, but these studies are greatly underpowered [42■,43]. 
Comparison between studies is limited by the highly variable timing of ART initiation, ART 
regimen and follow-up periods as well as the different measures of the HIV reservoir.
FUTURE RESEARCH
Most of the studies that have demonstrated the ability of early ART at reducing the size of 
the latent reservoir have been conducted on cells isolated from peripheral blood. Little 
information is known on the establishment of the reservoir in tissues (particularly the major 
anatomical HIV reservoirs such as the gut and lymph nodes) at the earliest stage of 
infection. This limitation is obviously attributable to the difficulty in accessing these 
samples, but also to the lack of a sensitive, reproducible and flexible assay that can measure 
a few latently infected cells harboring replication-competent HIV. Alleviating this technical 
limitation would also allow a better understanding of the relative importance of each 
memory T-cell subset to HIV persistence, as well as the capacity of early ART at interfering 
with the establishment of latency in these discrete subsets of cells.
The persistence of infection in TCM after 10 years of ART in the study by Buzon et al. 
[27■■] suggests that treatment within the first 6 months of infection is not early enough, but 
it remains unknown what the window of opportunity to intervene is before reaching the 
‘point of no return.’ Theoretically, the earlier ART is initiated (i.e., Fiebig stages I and II) 
[28], the higher should be the chance for HIV remission. However, the PTCs in the 
VISCONTI cohort were mainly those treated in Fiebig IV and V stages [11■■]. 
Understanding the precise timing of ART initiation that has the greatest impact on HIV 
Ananworanich et al. Page 5






















reservoirs will require careful characterization of patients at time of ART initiation for their 
history of HIV exposure and viro-logic and serologic markers of HIV. A concerted effort to 
evaluate and identify AHI staging system that could predict outcomes relevant to HIV cure 
(e.g., HIV reservoir size) would be a major advancement. Additionally, there is a dearth of 
data on the HIV-specific immune responses following early ART. It is possible that such 
immune responses are blunted with rapid treatment and viral suppression, as evidenced by 
the higher proportion of early treated individuals who remain HIV seronegative compared 
with the later treatment initiators [44,45]. Knowledge on the association between existing 
immune responses and HIV reservoirs after AHI treatment will inform future immune-based 
strategies to eliminate latently infected cells.
CONCLUSION
It is clear that early ART results in lower reservoir size which could delay the time to viral 
rebound when ART is interrupted, as has been demonstrated in the Mississippi child. 
However, reaching sustained HIV remission or cure will require not only reduction size of 
the HIV reservoir, but also, to modify the distribution of the replication-competent HIV 
reservoir in CD4+ T cells and tissues. ART initiated during AHI, however, may be the first 
critical step in the path aimed at HIV remission or cure by limiting the HIV reservoir 
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• HIV persistence is established early in AHI in long-lived memory CD4+ T cells 
that are nonpermissive for viral gene expression, therefore, not eliminated by 
immune surveillance or ART.
• ART instituted during AHI can reduce the HIV reservoir size to a greater extent 
than when treatment is given in chronic HIV. However, infection generally 
persists in memory CD4+ T cells in most early treated individuals.
• Recent data suggest that treatment in the earliest AHI stage (Fiebig I) may 
protect central memory CD4+ T cells from infection and skew the distribution of 
latently infected cells to the shorter lived memory CD4+ T cells as is the case in 
individuals who control HIV without ART (elite controllers and PTCs).
• ART in AHI may be the first critical step in the path to achieve HIV remission 
by containing HIV reservoir seeding prior to instituting additional interventions 
to eliminate all latently infected cells.
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The size and composition of the latent HIV reservoir is affected by early ART. (a) Subsets 
of CD4 T cells can be identified based on the levels of expression of several cellular markers 
including CD45RA, CCR7, CD27 and CD95. The pathway of T cell differentiation, that is, 
the sequence of development of the different T-cell subsets, remains elusive in humans, and 
it is unclear if the differentiation pathway is linear or branched, one-way or reversible [31]. 
(b) In chronically infected patients, the contribution of TCM cells to the overall pool of 
infected cells is important [30]. As these cells are long lived, they survive after years of 
ART and represent the major latent HIV reservoir in patients who started ART during 
chronic infection [24■]. The contribution of TSCM cells also increases with time [27■■]. 
Patients with acute or recent infection display a small size of the reservoir (as depicted by a 
reduced size of the grey box). In addition, their TCM cells may be relatively preserved from 
infection, with a greater contribution of short-lived cells. After years of ART, this may result 
in a reservoir of a very small magnitude. ART, antiretroviral therapy.
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